Intelligent Solutions for Oral Drug Delivery SM
Welcome to Enteris BioPharma, the drug delivery partner of choice for the oral formulation of BCS class II, III and IV compounds, including peptides.
The pharmaceutical community has long sought more effective ways to increase physician acceptance and patient compliance for medications in a variety of therapeutic indications. Enteris BioPharma has emerged as a leader in innovative oral dosage formulations with our proprietary cutting edge platform technology.
Enteris’ simple, elegant and scalable oral delivery solution has overcome previously unmet challenges in both permeability and solubility, with a demonstrated track record of clinical success across a range of compounds. We are dedicated to building long term strategic relationships and offer our partners a robust formulation strategy that begins with in-vitro characterization of their compound and goes through optimizing tablet formulations that provide fully optimized GMP clinical trial material.
Read more about our technology services.
“We are focused on solving challenging formulation issues for our partners using our proprietary, cutting edge, delivery technology. Our combined strengths in formulation development and manufacturing uniquely position us to be an industry leader in overcoming the formulation challenges to deliver peptides and small molecules orally.”
President and Chief Financial Officer
“Enteris has something unique, a proprietary technology platform for convenient oral delivery of peptides and small molecules that are otherwise delivered by injection. I think that’s remarkable and valuable. The Business Development and Licensing team engages with clients to formulate a collaboration that fits the opportunity and circumstances while rewarding both partners for the innovation they have created.”
Vice President, Business Development
“We are dedicated to providing our partners a turnkey solution that enables them to rapidly evaluate and implement our delivery technology in a robust pharmaceutical development strategy. With our proven capabilities, we are able to deliver a full 3.2.P filing package and Clinical Trial Material to allow partners quick entry into clinical evaluation.”
Paul Shields, Ph.D.
Vice President, Operations